Davis Gregory D
Head of Research & Technology
Davis Gregory D has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: May 27, 2026.
On the most recent filing, Davis Gregory D is listed as Head of Research & Technology at SANGAMO THERAPEUTICS, INC. Inside the rolling window, Davis Gregory D reported no open-market purchases and 1 open-market sale totaling $18K in SGMO.
Companies traded
Other insiders at SGMO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$18K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Davis Gregory D made?
Davis Gregory D has filed 6 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Davis Gregory D trade?
Davis Gregory D has filed SEC Form 4 disclosures for 1 company, including SGMO.
When was Davis Gregory D's most recent SEC Form 4 filing?
Davis Gregory D's most recent SEC Form 4 filing on Tracefour is dated May 27, 2026.
What is Davis Gregory D's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Davis Gregory D is listed as Head of Research & Technology.
What is Davis Gregory D's total buy and sell value in the current window?
Inside the rolling retention window, Davis Gregory D bought $0 and sold $18K based on SEC Form 4 filings.
What was Davis Gregory D's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 69,827 SGMO shares on 2026-04-22, worth $18K, per SEC Form 4 filings.